This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Watson, P. A. Articles by Sawyers, C. L. Search for Related Content PubMed PubMed Citation Articles by Watson, P. A. Articles by Sawyers, C. L.

Context-Dependent Hormone-Refractory Progression Revealed through Characterization of a Novel Murine Prostate Cancer Cell Line

¹ Division of Hematology/Oncology, Department of Medicine, and ² Howard Hughes Medical Institute, University of California at Los Angeles, Los Angeles, California; and ³ Section of Hematology/Oncology, University of Chicago, Chicago, Illinois

Requests for reprints: Charles L. Sawyers, University of California at Los Angeles, 9-240 Factor, 10833 Le Conte Avenue, Los Angeles, CA 90095. E-mail: csawyers{at}mednet.ucla.edu.

Insights into the molecular basis of hormone-refractory prostate cancer have principally relied on human prostate cancer cell lines, all of which were derived from patients who had already failed hormonal therapy. Recent progress in developing genetically engineered mouse prostate cancer models provides an opportunity to isolate novel cell lines from animals never exposed to hormone ablation, avoiding any potential bias conferred by the selective pressure of the castrate environment. Here we report the isolation of such a cell line (Myc-CaP) from a c-myc transgenic mouse with prostate cancer. Myc-CaP cells have an amplified androgen receptor gene despite no prior exposure to androgen withdrawal and they retain androgen-dependent transgene expression as well as androgen-dependent growth in soft agar and in mice. Reexpression of c-Myc from a hormone-independent promoter rescues growth in androgen-depleted agar but not in castrated mice, showing a clear distinction between the molecular requirements for hormone-refractory growth in vitro versus in vivo. Myc-CaP cells represent a unique reagent for dissecting discreet steps in hormone-refractory prostate cancer progression and show the general utility of using genetically engineered mouse models for establishing new prostate cancer cell lines. (Cancer Res 2005; 65(24): 11565-71)

This article has been cited by other articles:

				N. Kobayashi, R. J. Barnard, J. Said, J. Hong-Gonzalez, D. M. Corman, M. Ku, N. B. Doan, D. Gui, D. Elashoff, P. Cohen, et al. Effect of Low-Fat Diet on Development of Prostate Cancer and Akt Phosphorylation in the Hi-Myc Transgenic Mouse Model Cancer Res., April 15, 2008; 68(8): 3066 - 3073. [Abstract] [Full Text] [PDF]

				M. M. Shen and C. Abate-Shen Pten Inactivation and the Emergence of Androgen-Independent Prostate Cancer Cancer Res., July 15, 2007; 67(14): 6535 - 6538. [Abstract] [Full Text] [PDF]

				J. Jiao, S. Wang, R. Qiao, I. Vivanco, P. A. Watson, C. L. Sawyers, and H. Wu Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development Cancer Res., July 1, 2007; 67(13): 6083 - 6091. [Abstract] [Full Text] [PDF]